Developing Selective Melanotropin 4 Ligands for the Neurodegernative Diseases

Technology #ua17-016

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Victor Hruby
Regents Professor Emeritus, Chemistry & Biochemistry
Minying Cai
Research Professor, Chemistry and Biochemistry
Managed By
Paul Eynott
Sr. Licensing Manager (520) 621-2878

Title: Developing Selective Melanotropin 4 Ligands for the Neurodegenerative Diseases

 

Invention: This technology is the development of ligands that selectively bind to the Melanocortin 3 Receptor (MC3R) and Melanocortin 4 Receptor (MC4R) and modulate receptor activity as a therapy for Alzheimer’s, Parkinson’s, or other neurodegenerative diseases. The melanocortin receptor ligand is bound to an MC3R and/or MC4R selective moiety, which allows the complex to cross the blood brain barrier. The ligand-moiety complex has improved selectivity to MC3R and/or MC4R and anti-inflammation function.

 

Background: MC3R and MC4R are under-targeted in treatments for neurodegenerative diseases. In addition, existing ligand analogues have low selectivity and anti-inflammation function relative to the present invention.

 

Applications:

  • Treatment for neurodegenerative diseases

 

Advantages:

  • Targets a unique pathway in neurodegenerative disease development
  • Ligand-moiety complex has improved selectivity for the MC3R and/or MC4R receptors
  • Retains a better anti-inflammation function than existing ligand analogues

 

Licensing Manager:

Paul Eynott

PaulE@tla.arizona.edu

(520) 471-2687